692 related articles for article (PubMed ID: 30928346)
1. Thrombotic Thrombocytopenic Purpura: Beyond Empiricism and Plasma Exchange.
Tsai HM
Am J Med; 2019 Sep; 132(9):1032-1037. PubMed ID: 30928346
[TBL] [Abstract][Full Text] [Related]
2. Transfusion of Platelets Loaded With Recombinant ADAMTS13 (A Disintegrin and Metalloprotease With Thrombospondin Type 1 Repeats-13) Is Efficacious for Inhibiting Arterial Thrombosis Associated With Thrombotic Thrombocytopenic Purpura.
Abdelgawwad MS; Cao W; Zheng L; Kocher NK; Williams LA; Zheng XL
Arterioscler Thromb Vasc Biol; 2018 Nov; 38(11):2731-2743. PubMed ID: 30354235
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic plasma exchange in thrombotic thrombocytopenic purpura.
Picod A; Provôt F; Coppo P
Presse Med; 2019 Nov; 48(11 Pt 2):319-327. PubMed ID: 31759790
[TBL] [Abstract][Full Text] [Related]
4. A critical evaluation of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura.
Gómez-Seguí I; Fernández-Zarzoso M; de la Rubia J
Expert Rev Hematol; 2020 Nov; 13(11):1153-1164. PubMed ID: 32876503
[No Abstract] [Full Text] [Related]
5. Caplacizumab to treat immune-mediated thrombotic thrombocytopenic purpura.
Poullin P; Bornet C; Veyradier A; Coppo P
Drugs Today (Barc); 2019 Jun; 55(6):367-376. PubMed ID: 31250841
[TBL] [Abstract][Full Text] [Related]
6. Thrombotic thrombocytopenic purpura.
Joly BS; Coppo P; Veyradier A
Blood; 2017 May; 129(21):2836-2846. PubMed ID: 28416507
[TBL] [Abstract][Full Text] [Related]
7. Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura.
Scully M; Cataland SR; Peyvandi F; Coppo P; Knöbl P; Kremer Hovinga JA; Metjian A; de la Rubia J; Pavenski K; Callewaert F; Biswas D; De Winter H; Zeldin RK;
N Engl J Med; 2019 Jan; 380(4):335-346. PubMed ID: 30625070
[TBL] [Abstract][Full Text] [Related]
8. Current and Future Perspectives on ADAMTS13 and Thrombotic Thrombocytopenic Purpura.
Roose E; Joly BS
Hamostaseologie; 2020 Aug; 40(3):322-336. PubMed ID: 32726827
[TBL] [Abstract][Full Text] [Related]
9. Taking Empiricism out of Immune Thrombotic Thrombocytopenic Purpura: Current and Future Treatment Strategies.
Mazepa MA; Park YA; Raval JS
Transfus Med Rev; 2019 Oct; 33(4):248-255. PubMed ID: 31645275
[TBL] [Abstract][Full Text] [Related]
10. Caplacizumab: an anti-von Willebrand factor antibody for the treatment of thrombotic thrombocytopenic purpura.
Hollifield AL; Arnall JR; Moore DC
Am J Health Syst Pharm; 2020 Jul; 77(15):1201-1207. PubMed ID: 32588878
[TBL] [Abstract][Full Text] [Related]
11. Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.
Peyvandi F; Scully M; Kremer Hovinga JA; Cataland S; Knöbl P; Wu H; Artoni A; Westwood JP; Mansouri Taleghani M; Jilma B; Callewaert F; Ulrichts H; Duby C; Tersago D;
N Engl J Med; 2016 Feb; 374(6):511-22. PubMed ID: 26863353
[TBL] [Abstract][Full Text] [Related]
12. Child-onset and adolescent-onset acquired thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency: a cohort study of the French national registry for thrombotic microangiopathy.
Joly BS; Stepanian A; Leblanc T; Hajage D; Chambost H; Harambat J; Fouyssac F; Guigonis V; Leverger G; Ulinski T; Kwon T; Loirat C; Coppo P; Veyradier A;
Lancet Haematol; 2016 Nov; 3(11):e537-e546. PubMed ID: 27720178
[TBL] [Abstract][Full Text] [Related]
13. Caplacizumab for relapsing thrombotic thrombocytopenic purpura.
Kaczmarek V; Holle J; Astudillo R; Kempf C; Bufler P; Müller D
Pediatr Nephrol; 2019 Sep; 34(9):1625-1628. PubMed ID: 31177334
[TBL] [Abstract][Full Text] [Related]
14. Beyond plasma exchange: novel therapies for thrombotic thrombocytopenic purpura.
Dane K; Chaturvedi S
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):539-547. PubMed ID: 30504355
[TBL] [Abstract][Full Text] [Related]
15. Caplacizumab: a change in the paradigm of thrombotic thrombocytopenic purpura treatment.
le Besnerais M; Veyradier A; Benhamou Y; Coppo P
Expert Opin Biol Ther; 2019 Nov; 19(11):1127-1134. PubMed ID: 31359806
[No Abstract] [Full Text] [Related]
16. [Treatment of immune-mediated thrombotic thrombocytopenic purpura: A decisive turning point].
Poullin P
Transfus Clin Biol; 2021 Nov; 28(4):380-385. PubMed ID: 34464709
[TBL] [Abstract][Full Text] [Related]
17. Inherited thrombotic thrombocytopenic purpura mimicking immune thrombocytopenic purpura during pregnancy: a case report.
Romão de Souza V; Beatriz Cavalcante de Oliveira A; Maria Vanderlei A; Queiroz da Mota Silveira Aroucha A; Pontes Duarte B; Nunes Machado A; Netto Chaer L; Wanderley de Barros Correia C; da Conceição de Barros Correia M; Freire Hazin Costa M
J Med Case Rep; 2018 Jan; 12(1):15. PubMed ID: 29357939
[TBL] [Abstract][Full Text] [Related]
18. When targeted therapies alleviate the burden of TPE: The example of immune-mediated TTP.
Picod A; Coppo P
Transfus Apher Sci; 2019 Jun; 58(3):273-277. PubMed ID: 31018909
[TBL] [Abstract][Full Text] [Related]
19. Understanding therapeutic targets in thrombotic thrombocytopenic purpura.
Joly BS; Vanhoorelbeke K; Veyradier A
Intensive Care Med; 2017 Sep; 43(9):1398-1400. PubMed ID: 28116452
[No Abstract] [Full Text] [Related]
20. Thrombotic thrombocytopenic purpura: pathogenesis, diagnosis and potential novel therapeutics.
Saha M; McDaniel JK; Zheng XL
J Thromb Haemost; 2017 Oct; 15(10):1889-1900. PubMed ID: 28662310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
